- Home
- EMX vs IKT Comparison
EMX vs IKT Comparison
Compare EMX & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMX
- IKT
- Stock Information
- Founded
- EMX N/A
- IKT 2008
- Country
- EMX Canada
- IKT United States
- Employees
- EMX N/A
- IKT N/A
- Industry
- EMX
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- EMX
- IKT Health Care
- Exchange
- EMX Nasdaq
- IKT Nasdaq
- Market Cap
- EMX 196.2M
- IKT 159.2M
- IPO Year
- EMX N/A
- IKT 2020
- Fundamental
- Price
- EMX $1.70
- IKT $2.72
- Analyst Decision
- EMX Strong Buy
- IKT Strong Buy
- Analyst Count
- EMX 1
- IKT 2
- Target Price
- EMX $7.00
- IKT $6.50
- AVG Volume (30 Days)
- EMX 287.5K
- IKT 288.1K
- Earning Date
- EMX 11-07-2024
- IKT 11-14-2024
- Dividend Yield
- EMX N/A
- IKT N/A
- EPS Growth
- EMX N/A
- IKT N/A
- EPS
- EMX N/A
- IKT N/A
- Revenue
- EMX $26,818,000.00
- IKT $1.00
- Revenue This Year
- EMX N/A
- IKT N/A
- Revenue Next Year
- EMX $2.34
- IKT N/A
- P/E Ratio
- EMX N/A
- IKT N/A
- Revenue Growth
- EMX 25.53
- IKT N/A
- 52 Week Low
- EMX $1.41
- IKT $1.12
- 52 Week High
- EMX $2.15
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- EMX 46.20
- IKT 41.71
- Support Level
- EMX $1.69
- IKT $2.55
- Resistance Level
- EMX $1.74
- IKT $2.90
- Average True Range (ATR)
- EMX 0.04
- IKT 0.29
- MACD
- EMX -0.00
- IKT -0.08
- Stochastic Oscillator
- EMX 21.43
- IKT 18.09
About EMX EMX Royalty Corporation (Canada)
EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco, and Australia.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.